Binnopharm is a pharmaceuticals company that operates two advanced pharmaceutical plants that adhere to GMP (good vanufacturing practices) international quality standards. Binnopharm produces six dosage forms: ampoules, syringes, aerosols, pills, capsules and solutions. 

Business description

Binnopharm develops and manufactures drugs for the treatment of socially important diseases (respiratory diseases, pulmonology, neurology, nephrology, infectious diseases).

Binnopharm comprises one of the largest full-cycle biopharmaceutical facilities in Russia with an area of 32,000 sq m; LLC Alium, a modern plant producing infusion solutions; and Binnopharm Distribution an in-house distributor of medicines produced both by Binnopharm/Alium and by third parties.

The company is developing original combinations, biosimilar drugs and unique medications belonging to different treatment groups: pulmonology, neurology, cardiology, gastroenterology and endocrinology.

Binnopharm has the largest GMP facilities in Russia for the production of vaccines in ampoules (up to 80m ampoules per year) and a unique, fully equipped quality control laboratory. Over the past seven years, Binnopharm has been covering the bulk of the Russian state's demand for Hepatitis B vaccine.

The company employs over 300 people, including an R&D group and a marketing and sales team, which were formed in 2015-2016.

Binnopharm's key operating objectives for 2016 include aggressive marketing and increased sales of Binnopharm products for pulmonology and neurology applications, and the registration and launch of several new products. 

Key Executives

Alexey Chupin


Dmitry Zubov

Chairman of the Board of Directors

Corporate website: